AstraZeneca PLC (AZNCF)
OTCMKTS
· Delayed Price · Currency is USD
142.75
-2.88 (-1.97%)
Jun 5, 2025, 3:39 PM EDT
AstraZeneca Employees
AstraZeneca had 94,300 employees as of December 31, 2024. The number of employees increased by 4,400 or 4.89% compared to the previous year.
Employees
94,300
Change (1Y)
4,400
Growth (1Y)
4.89%
Revenue / Employee
$583,054
Profits / Employee
$82,418
Market Cap
226.14B
Employees Chart
Employees History
Related Stocks
Company Name | Employees |
---|---|
Endo Inc. | 3,116 |
Tian'an Technology Group | 8 |
Elite Pharmaceuticals | 64 |
Glass House Brands | 374 |
CytoDyn | 9 |
Northwest Biotherapeutics | 25 |
American Oncology Network | 1,914 |
Silence Therapeutics | 116 |
AstraZeneca News
- 3 days ago - Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO - CNBC
- 4 days ago - AstraZeneca says Enhertu, Perjeta combo cuts death risk in breast cancer - Seeking Alpha
- 4 days ago - AstraZeneca CEO on breast cancer drug trial: This is the future of cancer treatment - CNBC
- 4 days ago - How AstraZeneca Is Playing Its Cancer Cards To Become An $80 Billion Pharma - Investor's Business Daily
- 4 days ago - ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial - Benzinga
- 4 days ago - ENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast09 Phase 3 Trial - Benzinga
- 4 days ago - Experimental AstraZeneca pill helps cut risk of breast cancer progression - CNBC
- 5 days ago - Notable healthcare headlines for the week: AstraZeneca, Eli Lilly, Bristol Myers in focus - Seeking Alpha